Healthcare penny stocks tend to be the largest movers among other penny stocks. This is mainly due to the amount of news they release. For example, any development in treatment becomes a news catalyst, which happens more often than other news.
Driven Deliveries Inc. (DRVD)
Driven Deliveries Inc. (DRVD) is primarily a technology company so why include it with other healthcare penny stocks? It is included because of what Driven’s technology is capable of, delivering medical and recreational marijuana. Medical marijuana legality is sweeping across the US which is only expanding the future demand for the services Driven provides.
More studies are beginning to show the positive effects of marijuana in relation to stress and pain relief. These studies make Driven’s recent announcement way more important. Driven revealed a partnership with Pure Ratios, a company selling 96-hour pain relief CBD and THC patches. This product is the only of its kind as it bypasses the digestive process and is absorbed directly into the bloodstream.
[REPORT] One of the Only Public Cannabis Delivery Services in the United States…Here’s What To Know
Christian Schenk, CEO of Driven, stated, “We believe that our best-in-class delivery platform coupled with Pure Ratio’s proven popular brands will provide a strong synergistic relationship between the companies. We look forward to expanding our customer base while increasing revenue and enhancing our overall brand recognition. Management has already identified several similar popular brands that it intends to add to our platform in the near future.”
Biocept Inc (BIOC)
Biocept Inc (BIOC) is a healthcare company that uses liquid biopsy technology to assess several forms of cancer for physicians. Biocept has their own liquid biopsy platform known as Target SelectorTM which can analyze tumor markers.
Recently, Biocept announced a new Target SelectorTM platform for breast cancer. It is Biocept’s second tumor-specific panel and will help target the second leading cause of death for women. In addition, Biocept’s platform allows medical personnel to evaluate patients with metastatic breast cancer which is usually very difficult. This news has brought strong volume and a 11% pre-market move.
Cesca Therapeutics Inc. (KOOL)
Cesca Therapeutics Inc. (KOOL) is a medical device healthcare company for cell-based therapeutics. Cesca is an affiliate of the BoyaLife Group which is based out of China. Cesca is using its AutoXpress platform to meet the needs regarding cardio, vascular, and immune diseases.
One of Cesca’s subsidiaries, ThermoGenesis, recently received approval for its Next-Gen AXP II System for cord blood processing. The AXP II System allows for the processing and storage of hematopoietic stem call concentrates. Also, multiple cord blood units can be processed in one centrifuge. Thanks to this approval, Cesca’s stock increased by more than 40%.
PhaseBio Pharmaceuticals Inc. (PHAS)
PhaseBio Pharmaceuticals Inc. (PHAS) is a biopharmaceutical company whose primary goal is creating and selling treatments to orphan diseases. Their primary drug is called PB2452 which reverses antiplatelet activity. PB2452 recently received positive preliminary results from Phase 2a clinical trial. These results pushed the stock from $12.19 to $14.08 on June 18th.
“If approved, PB2452 could help address these critical unmet medical needs by enhancing the safety profile of ticagrelor, which has the potential to become the only antiplatelet therapy on the market with a specific reversal agent. We look forward to reporting full results from the Phase 2a trial at an upcoming medical congress.”
John Lee, M.D., Ph.D., Chief Medical Officer of PhaseBio